TIME UNTIL INSULIN INITIATION FOR CANAGLIFLOZIN VERSUS DAPAGLIFLOZIN AND EMPAGLIFLOZIN IN DUAL AND TRIPLE THERAPY FOR TYPE 2 DIABETES MELLITUS IN THE UNITED KINGDOM
Author(s)
Schroeder M1, Chan E2, Willis M3, Johansen P3, Nilsson A3, Schubert A4, Neslusan C5
1Janssen-Cilag UK, High Wycombe, UK, 2Janssen-Cilag Ltd, High Wycombe, UK, 3The Swedish Institute for Health Economics, Lund, Sweden, 4Janssen-Cilag Poland, Warsaw, Poland, 5Janssen Global Services, LLC, Raritan, NJ, USA
OBJECTIVES: Insulin therapy is associated with weight gain and hypoglycemia, and patients and physicians generally prefer to postpone insulin use. SGLT2 inhibitors provide substantial and sustained HbA1c lowering, weight loss, and blood pressure control in patients with T2DM, and are generally well tolerated. Indirect comparisons of clinical trial data suggest that these agents have differential efficacy. For example, a recent Bayesian network meta-analysis (NMA) demonstrated that CANA 300mg provided a larger HbA1c reduction versus DAPA and EMPA when added to background metformin at 104 weeks; CANA 100mg showed comparable glycemic efficacy. The objective of this analysis was to estimate the time to insulin rescue therapy with CANA versus DAPA and EMPA in dual and triple therapy in the UK healthcare setting. METHODS: The validated Economic and Health Outcomes Model of T2DM was used to simulate patient healthcare costs, benefits, and outcomes over 40 years. Population characteristics were sourced from a pooled analysis of CANA trials. Treatment effects were sourced primarily from NMAs at 26 weeks. Dose increases for CANA and EMPA were modeled as per product labels. Insulin rescue therapy consisted of basal insulin initiated when HbA1c >7.5% or when eGFR declined below values specified within the product labels. Prandial insulin was subsequently added as needed to maintain glycemic control. Insulin treatment effects were sourced from the literature. RESULTS: CANA delayed mean time until insulin therapy by 2.1 years versus DAPA (4.7 vs 2.6) and 0.2 years versus EMPA (4.7 vs 4.5) in dual therapy, and by 2.2 years versus DAPA (5.4 vs 3.2) and 0.8 years versus EMPA (5.4 vs 4.6) in triple therapy. CONCLUSIONS: Long-term simulations suggest that CANA may be associated with longer delays in starting insulin therapy versus DAPA and EMPA in both dual and triple therapy in the UK.
Conference/Value in Health Info
2016-05, ISPOR 2016, Washington DC, USA
Value in Health, Vol. 19, No. 3 (May 2016)
Code
PDB10
Topic
Clinical Outcomes
Topic Subcategory
Comparative Effectiveness or Efficacy
Disease
Diabetes/Endocrine/Metabolic Disorders